Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
A US-based retrospective cohort study has shown no difference in the rates of mortality and cardiovascular disease (CVD) with initiation and continuous use of either analogue or human insulin in insulin-naïve adults with type 2 diabetes (T2D).
The amphetamine derivative fenfluramine, previously marketed as an appetite suppressant to manage obesity, delivers a different promise in a new phase III trial by showing its anti-epileptic potential in children and young adults with Dravet syndrome.
Impaired endothelium-independent vascular smooth muscle reactivity negotiates the relationship between poor cognitive performance and high visceral adiposity in elderly adults with type 2 diabetes (T2D), according to a new Singapore study.
A large Canadian population-based study links living near major roads and highways with higher incidence of non-Alzheimer’s dementia (NAD), Parkinson’s disease (PD), Alzheimer’s disease (AD) and multiple sclerosis (MS).
A community-based prospective study of 921 older adults finds evidence that a diet high in flavonols, particularly kaempferol and isorhamnetin, may be protective against the development of Alzheimer’s dementia.
The dual orexin receptor antagonist lemborexant effectively promotes sleep by improving both the onset and maintenance of sleep compared with placebo or zolpidem in older patients with insomnia, the SUNRISE 1* trial has shown.
The GLP-1 receptor agonist* dulaglutide may reduce the incidence of stroke, particularly ischaemic stroke, in individuals with type 2 diabetes (T2D) and cardiovascular (CV) risk factors, according to findings of an exploratory analysis of the REWIND** trial.